Endocrine therapy is recommended for IBC patients with estrogen receptor-positive (ER +) and/or progesterone receptor-positive (PR +) by the National Comprehensive Cancer Network (NCCN) guidelines. Here, ESR1 is linked to inflammatory breast carcinoma.